Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2025-03-28 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
公司章程（2025年3月）
Governance Information Classification · 100% confidence The document is titled "公司章程" which translates to "Articles of Association" or "Company Bylaws". It contains detailed provisions about the company's organization, shareholder rights, board of directors, management, financial accounting, profit distribution, auditing, and other governance matters. It references Chinese company law and securities law, and includes detailed rules on shareholder meetings, voting, share issuance, and other corporate governance topics. This document is a governance document that sets out the internal rules and structure of the company rather than a financial report, earnings release, or announcement. It is not a report of financial results or an announcement of voting results. It is not a proxy statement or remuneration report. It is a comprehensive governance framework document. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is the full governance document, not just an announcement or summary.
2025-03-28 Chinese
2024年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2024年度监事会工作报告" which translates to "2024 Supervisory Board Work Report". It details the supervisory board's activities, including meetings held, opinions on company operations, financial status, internal controls, and compliance with laws and regulations. It includes oversight of financial reports, internal control evaluations, and audit firm reappointment. The document is a detailed report from the supervisory board on their work and oversight for the year 2024. It is not an announcement or a brief summary but a substantive report on management and supervisory activities. This fits best under the category of Management Reports (MDA), which covers management's detailed explanation of financial results, business trends, and outlook, including supervisory board reports on company governance and oversight.
2025-03-28 Chinese
中信证券股份有限公司关于重庆博腾制药科技股份有限公司2024年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (special inspection report) by CITIC Securities regarding the 2024 annual fundraising funds deposit and usage of Chongqing Boteng Pharmaceutical Technology Co., Ltd. It details the amount of funds raised, their deposit, usage, changes in investment projects, and compliance with regulatory requirements. It includes detailed financial figures related to fundraising and usage, as well as audit opinions from an accounting firm. The document is a standalone audit-type report focusing on the management and use of raised funds, not a full annual or interim financial report. It is not an announcement or a brief notice but a detailed verification report. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory checks related to accounting and fund usage. Therefore, the correct classification is AR with high confidence.
2025-03-28 Chinese
关于2024年度计提资产减值准备及部分资产报废的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding the provision for asset impairment and disposal of certain assets for the fiscal year 2024. It details the amounts of impairment provisions for various asset categories, the impact on net profit, and includes opinions from the board and supervisory committee. The document references the 2024 fiscal year and the company's accounting policies but does not contain full financial statements or comprehensive financial data typical of an annual or interim report. The document length is 2309 characters, which is relatively short and reads as an announcement of a specific accounting action rather than a full report. It is not a certification letter, call transcript, or voting result announcement. It is a regulatory announcement about asset impairment provisions and asset disposal, which fits best under Regulatory Filings (RNS) as it does not constitute a full audit report or annual report but is a compliance disclosure related to financial reporting.
2025-03-28 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告' which translates to 'Annual Report' and contains detailed company information, financial data, management discussion and analysis, risk factors, and other comprehensive disclosures typical of a full annual report. It includes financial statements, management commentary, company overview, and detailed notes on business operations and risks. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is merely a notice of report publication or a certification. Therefore, the document fits the definition of an Annual Report (10-K).
2025-03-28 Chinese
2024年度非经营性资金占用及其他关联资金往来情况的专项审计说明
Audit Report / Information Classification · 95% confidence The document is a specialized audit report focusing on non-operating fund occupation and other related party fund transactions for the fiscal year 2024. It includes an audit opinion from a registered accounting firm, references to regulatory guidelines, and detailed financial tables related to these transactions. The document is titled as a "专项审计说明" (special audit explanation) and contains audit conclusions and responsibilities, which are typical characteristics of an Audit Report / Information filing. The document length is 3412 characters, which is relatively short but contains substantive audit content rather than just an announcement or certification. Therefore, it is not a Report Publication Announcement or Regulatory Filing. It is not a full Annual Report or Interim Report as it focuses on a specific audit area rather than comprehensive financial statements. Hence, the appropriate classification is Audit Report / Information (AR).
2025-03-28 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.